Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

  • Chaparro, M.
  • Verreth, A.
  • Lobaton, T.
  • Gravito-Soares, E.
  • Julsgaard, M.
  • Savarino, E.
  • Magro, F.
  • Biron, I.A.
  • Lopez-Serrano, P.
  • Casanova, M.J.
  • Gompertz, M.
  • Vitor, S.
  • Arroyo, M.
  • Pugliese, D.
  • Zabana, Y.
  • Vicente, R.
  • Aguas, M.
  • Shitrit, A.B.G.
  • Gutierrez, A.
  • Doherty, G.A.
  • Fernandez-Salazar, L.
  • Cadilla, J.M.
  • Huguet, J.M.
  • O''Toole, A.
  • Stasi, E.
  • Marcos, N.M.
  • Villoria, A.
  • Karmiris, K.
  • Rahier, J.F.
  • Rodriguez, C.
  • Palomares, M.D.L.
  • Fiorino, G.
  • Benitez, J.M.
  • Principi, M.
  • Naftali, T.
  • Taxonera, C.
  • Mantzaris, G.
  • Sebkova, L.
  • Iade, B.
  • Lissner, D.
  • Bradley, I.F.
  • Roman, A.L.S.
  • Marin-Jimenez, I.
  • Merino, O.
  • Sierra, M.
  • Van Domselaar, M.
  • Caprioli, F.
  • Guerra, I.
  • Peixe, P.
  • Piqueras, M.
  • Rodriguez-Lago, I.
  • Ber, Y.
  • van Hoeve, K.
  • Torres, P.
  • Gravito-Soares, M.
  • Rudbeck-Resdal, D.
  • Bartolo, O.
  • Peixoto, A.
  • Martin, G.
  • Armuzzi, A.
  • Garre, A.
  • Donday, M.G.
  • de Carpi, F.J.M.
  • Gisbert, J.P.
OBJECTIVES: The long-term safety of exposure to anti-tumor necrosis factor (anti-TNF alpha) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNF alpha drugs in utero with that of children who were not exposed to the drugs. METHODS: Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNF alpha medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNF alpha agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan-Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring. RESULTS: The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNF alpha agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8-1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5-4.3)). CONCLUSIONS: In utero exposure to anti-TNF alpha drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

  • Chaparro, M.
  • Barreiro-de Acosta, M.
  • Echarri, A.
  • Almendros, R.
  • Barrio, J.
  • Llao, J.
  • Gomollón, F.
  • Vera, M.
  • Cabriada, J.L.
  • Guardiola, J.
  • Guerra, I.
  • Beltrán, B.
  • Roncero, O.
  • Busquets, D.
  • Taxonera, C.
  • Calvet, X.
  • Ferreiro-Iglesias, R.
  • Ollero Pena, V.
  • Bernardo, D.
  • Donday, M.G.
  • Garre, A.
  • Godino, A.
  • Díaz, A.
  • Gisbert, J.P.
Objectives: (a) To evaluate the diagnostic accuracy of anti-TNF trough levels to predict mucosal healing in inflammatory bowel disease (IBD); (b) to determine the best cut-off point to predict mucosal healing in IBD patients treated with anti-TNF. Methods: This is a multicenter, prospective study. IBD patients under anti-TNF treatment for at least 6 months that had to undergo an endoscopy were included. Mucosal healing was defined as: Simple endoscopic score for Crohn’s Disease < 3 for Crohn’s disease (CD), Rutgeerts score < i2 for CD in postoperative setting, or Mayo endoscopic score = 1 for ulcerative colitis (UC). Anti-TNF concentrations were measured using SMART ELISAs at trough. Results: A total of 182 patients were included. Anti-TNF trough levels were significantly higher among patients that had mucosal healing than among those who did not. The area under the curve of infliximab for mucosal healing was 0.63 (best cutoff value 3.4 µg/mL), and for adalimumab 0.60 (best cutoff value 7.2 µg/mL). In the multivariate analysis, having anti-TNF drug levels above the cutoff values [odds ratio (OR) 3.1]) and having UC instead of CD (OR 4) were associated with a higher probability of having mucosal healing. Additionally, the need for an escalated dosage (OR 0.2) and current smoking habit (OR 0.2) were also associated with a lower probability of mucosal healing. Conclusions: There was an association between anti-TNF trough levels and mucosal healing in IBD patients; however, the accuracy of the determination of infliximab and adalimumab concentrations able to predict mucosal healing was suboptimal.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease

  • Chaparro, M
  • Aterido, A
  • Guerra, I
  • Iborra, M
  • Cabriada, JL
  • Bujanda, L
  • Taxonera, C
  • Garcia-Sanchez, V
  • Marin-Jimenez, I
  • Barreiro-de Acosta, M
  • Vera, I
  • Martin-Arranz, MD
  • Hernandez-Breijo, B
  • Mesonero, F
  • Sempere, L
  • Gomollon, F
  • Hinojosa, J
  • Bermejo, F
  • Beltran, B
  • Rodriguez-Pescador, A
  • Banales, JM
  • Olivares, D
  • Aguilar-Melero, P
  • Menchen, L
  • Ferreiro-Iglesias, R
  • Gomez, IB
  • Garcia, BB
  • Guijarro, LG
  • Marin, AC
  • Bernardo, D
  • Marsal, S
  • Julia, A
  • Gisbert, JP
Background: The effect of low-frequency functional variation on anti-tumor necrosis factor alpha (TNF) response in Crohn''s disease (CD) patients remains unexplored. The objective of this study was to investigate the impact of functional rare variants in clinical response to anti-TNF therapy in CD. Methods: CD anti-TNF naive patients starting anti-TNF treatment due to active disease [Crohn''s Disease Activity Index (CDAI > 150)] were included. The whole genome was sequenced using the Illumina Hiseq4000 platform. Clinical response was defined as a CDAI score <150 at week 14 of anti-TNF treatment. Low-frequency variants were annotated and classified according to their damaging potential. The whole genome of CD patients was screened to identify homozygous loss-of-function (LoF) variants. The TNF signaling pathway was tested for overabundance of damaging variants using the SKAT-O method. Functional implication of the associated rare variation was evaluated using cell-type epigenetic enrichment analyses. Results: A total of 41 consecutive CD patients were included; 3250 functional rare variants were identified (2682 damaging and 568 LoF variants). Two homozygous LoF mutations were found in HLA-B and HLA-DRB1 genes associated with lack of response and remission, respectively. Genome-wide LoF variants were enriched in epigenetic marks specific for the gastrointestinal tissue (colon, p = 4.11e-4; duodenum, p = 0.011). The burden of damaging variation in the TNF signaling pathway was associated with response to anti-TNF therapy (p = 0.016); damaging variants were enriched in epigenetic marks from CD8(+) (p = 6.01e-4) and CD4+ (p = 0.032) T cells. Conclusions: Functional rare variants are involved in the response to anti-TNF therapy in CD. Cell-type enrichment analysis suggests that the gut mucosa and CD8(+) T cells are the main mediators of this response.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease

  • Chaparro, M.
  • Garre, A.
  • Guerra, Veloz, M.F.
  • Vázquez Morón, J.M.
  • De Castro, M.L.
  • Leo, E.
  • Rodriguez, E.
  • Carbajo, A.Y.
  • Riestra, S.
  • Jiménez, I.
  • Calvet, X.
  • Bujanda, L.
  • Rivero, M.
  • Gomollón, F.
  • Benítez, J.M.
  • Bermejo, F.
  • Alcaide, N.
  • Gutiérrez, A.
  • Mañosa, M.
  • Iborra, M.
  • Lorente, R.
  • Rojas-Feria, M.
  • Barreiro-de Acosta, M.
  • Kolle, L.
  • Van Domselaar, M.
  • Amo, V.
  • Argüelles, F.
  • Ramírez, E.
  • Morell, A.
  • Bernardo, D.
  • Gisbert, J.P.
BACKGROUND AND AIMS: To evaluate the clinical outcomes in patients with IBD after switching from Remicade® to CT-P13 in comparison with patients who maintain Remicade®. METHODS: Patients under Remicade® who were in clinical remission with standard dosage at study entry were included. The ''switch cohort'' [SC] comprised patients who made the switch from Remicade® to CT-P13, and the ''non-switch'' cohort [NC] patients remained under Remicade®. RESULTS: A total of 476 patients were included: 199 [42%] in the SC and 277 [58%] in the NC. The median follow-up was 18 months in the SC and 23 months in the NC [p < 0.01]. Twenty-four out of 277 patients relapsed in the NC; the incidence of relapse was 5% per patient-year. The cumulative incidence of relapse was 2% at 6 months and 10% at 24 months in this group. Thirty-eight out of 199 patients relapsed in the SC; the incidence rate of relapse was 14% per patient-year. The cumulative incidence of relapse was 5% at 6 months and 28% at 24 months. In the multivariate analysis, the switch to CT-P13 was associated with a higher risk of relapse (HR = 3.5, 95% confidence interval [CI] = 2-6). Thirteen percent of patients had adverse events in the NC, compared with 6% in the SC [p < 0.05]. CONCLUSIONS: Switching from Remicade® to CT-P13 might be associated with a higher risk of clinical relapse, although this fact was not supported in our study by an increase in objective markers of inflammation. The nocebo effect might have influenced this result. Switching from Remicade® to CT-P13 was safe.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved

  • Guijarro, Luis G.
  • Cano-Martínez, David
  • Toledo-Lobo, M.Val
  • Salinas, Patricia Sanmartín
  • Chaparro, María
  • Gómez-Lahoz, Ana M.
  • Zoullas, Sofía
  • Rodríguez-Torres, Rosa
  • Román, Irene D.
  • Monasor, Laura Sebastián
  • Ruiz-Llorente, Lidia
  • del Carmen Boyano-Adánez, María
  • Guerra, Iván
  • Iborra, Marisa
  • Cabriada, José Luis
  • Bujanda, Luis
  • Taxonera, Carlos
  • García-Sánchez, Valle
  • Marín-Jiménez, Ignacio
  • Acosta, Manuel Barreiro-de
  • Vera, Isabel
  • Martín-Arranz, María Dolores
  • Mesonero, Francisco
  • Sempere, Laura
  • Gomollón, Fernando
  • Hinojosa, Joaquín
  • Alvarez-Mon, Melchor
  • Gisbert, Javier P.
  • Ortega, Miguel A.
  • Hernández-Breijo, Borja
Inflammatory bowel diseases (IBD), represented by ulcerative colitis (UC) and Crohn''s disease (CD), are characterized by chronic inflammation of the gastrointestinal tract, what leads to diarrhea, malnutrition, and weight loss. Depression of the growth hormone-insulin-like growth factor-1 axis (GH-IGF-1 axis) could be responsible of these symptoms. We demonstrate that long-term treatment (54 weeks) of adult CD patients with adalimumab (ADA) results in a decrease in serum IGF-1 without changes in serum IGF-1 binding protein (IGF1BP4). These results prompted us to conduct a preclinical study to test the efficiency of IGF-1 in the medication for experimental colitis. IGF-1 treatment of rats with DSS-induced colitis has a beneficial effect on the following circulating biochemical parameters: glucose, albumin, and total protein levels. In this experimental group we also observed healthy maintenance of colon size, body weight, and lean mass in comparison with the DSS-only group. Histological analysis revealed restoration of the mucosal barrier with the IGF-1 treatment, which was characterized by healthy quantities of mucin production, structural maintenance of adherers junctions (AJs), recuperation of E-cadherin and ß-catenin levels and decrease in infiltrating immune cells and in metalloproteinase-2 levels. The experimentally induced colitis caused activation of apoptosis markers, including cleaved caspase 3, caspase 8, and PARP and decreases cell-cycle checkpoint activators including phosphorylated Rb, cyclin E, and E2F1. The IGF-1 treatment inhibited cyclin E depletion and partially protects PARP levels. The beneficial effects of IGF-1 in experimental colitis could be explained by a re-sensitization of the IGF-1/IRS-1/AKT cascade to exogenous IGF-1. Given these results, we postulate that IGF-1 treatment of IBD patients could prove to be successful in reducing disease pathology. © 2021 The Authors
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

  • Aterido Ballonga, Adria
  • Guerra, Iván
  • Cabriada, Jose Luis
  • Marsal Barril, Sara
  • Julia Cano, Antonio
  • Chaparro, María
  • Bujanda, Luis
  • Iborra, Marisa
Adalimumab; Crohn’s disease; Infliximab, Adalimumab; Enfermedad de Crohn; Infliximab, Adalimumab; Malaltia de Crohn; Infliximab, Background: The effect of low-frequency functional variation on anti-tumor necrosis factor alpha (TNF) response in Crohn's disease (CD) patients remains unexplored. The objective of this study was to investigate the impact of functional rare variants in clinical response to anti-TNF therapy in CD. Methods: CD anti-TNF naïve patients starting anti-TNF treatment due to active disease [Crohn's Disease Activity Index (CDAI > 150)] were included. The whole genome was sequenced using the Illumina Hiseq4000 platform. Clinical response was defined as a CDAI score <150 at week 14 of anti-TNF treatment. Low-frequency variants were annotated and classified according to their damaging potential. The whole genome of CD patients was screened to identify homozygous loss-of-function (LoF) variants. The TNF signaling pathway was tested for overabundance of damaging variants using the SKAT-O method. Functional implication of the associated rare variation was evaluated using cell-type epigenetic enrichment analyses. Results: A total of 41 consecutive CD patients were included; 3250 functional rare variants were identified (2682 damaging and 568 LoF variants). Two homozygous LoF mutations were found in HLA-B and HLA-DRB1 genes associated with lack of response and remission, respectively. Genome-wide LoF variants were enriched in epigenetic marks specific for the gastrointestinal tissue (colon, p = 4.11e-4; duodenum, p = 0.011). The burden of damaging variation in the TNF signaling pathway was associated with response to anti-TNF therapy (p = 0.016); damaging variants were enriched in epigenetic marks from CD8+ (p = 6.01e-4) and CD4+ (p = 0.032) T cells. Conclusions: Functional rare variants are involved in the response to anti-TNF therapy in CD. Cell-type enrichment analysis suggests that the gut mucosa and CD8+ T cells are the main mediators of this response., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by grants from the "Instituto de Salud Carlos III" (FIS.12/02557 and PI13/00041).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease

  • Chaparro, María|||0000-0002-9275-4242
  • Aterido, Adrià|||0000-0003-1810-410X
  • Guerra, Iván|||0000-0002-5175-2515
  • Iborra, Marisa|||0000-0001-7360-7581
  • Cabriada, José Luis|||0000-0002-3068-5659
  • Bujanda, Luis|||0000-0002-4353-9968
  • Taxonera, Carlos|||0000-0001-9166-7350
  • García-Sánchez, Valle
  • Marín Jiménez, Ignacio|||0000-0001-5424-2484
  • Barreiro de-Acosta, Manuel|||0000-0001-5915-1477
  • Vera-Mendoza, Isabel
  • Martín-Arranz, María Dolores|||0000-0002-1872-0917
  • Hernández-Breijo, Borja
  • Mesonero, Francisco|||0000-0002-7864-8187
  • Sempere, Laura
  • Gomollón, Fernando|||0000-0003-0076-3529
  • Hinojosa, Joaquín
  • Bermejo, Fernando|||0000-0003-4610-0886
  • Beltrán, Belén|||0000-0002-7063-6376
  • Rodríguez-Pescador, Ainhoa
  • Banales, Jesus|||0000-0002-5224-2373
  • Olivares, David
  • Aguilar-Melero, Patricia
  • Menchén, Luis
  • Ferreiro Iglesias, Rocío|||0000-0002-0469-4332
  • Blázquez Gómez, Isabel
  • Benitez García, Beatriz
  • Guijarro, Luis G.
  • Marin, Alicia C.
  • Bernardo, D.|||0000-0002-2843-6696
  • Marsal, Sara|||0000-0001-5515-3854
  • Julià Cano, Antonio|||0000-0001-6064-3620
  • P. Gisbert, Javier|||0000-0003-2090-3445
Background: The effect of low-frequency functional variation on anti-tumor necrosis factor alpha (TNF) response in Crohn's disease (CD) patients remains unexplored. The objective of this study was to investigate the impact of functional rare variants in clinical response to anti-TNF therapy in CD. Methods: CD anti-TNF naïve patients starting anti-TNF treatment due to active disease [Crohn's Disease Activity Index (CDAI.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

  • Aterido Ballonga, Adria
  • Guerra, Iván
  • Cabriada, Jose Luis
  • Marsal Barril, Sara
  • Julia Cano, Antonio
  • Chaparro, María
  • Bujanda, Luis
  • Iborra, Marisa
Adalimumab; Crohn’s disease; Infliximab, Adalimumab; Enfermedad de Crohn; Infliximab, Adalimumab; Malaltia de Crohn; Infliximab, Background: The effect of low-frequency functional variation on anti-tumor necrosis factor alpha (TNF) response in Crohn's disease (CD) patients remains unexplored. The objective of this study was to investigate the impact of functional rare variants in clinical response to anti-TNF therapy in CD. Methods: CD anti-TNF naïve patients starting anti-TNF treatment due to active disease [Crohn's Disease Activity Index (CDAI > 150)] were included. The whole genome was sequenced using the Illumina Hiseq4000 platform. Clinical response was defined as a CDAI score <150 at week 14 of anti-TNF treatment. Low-frequency variants were annotated and classified according to their damaging potential. The whole genome of CD patients was screened to identify homozygous loss-of-function (LoF) variants. The TNF signaling pathway was tested for overabundance of damaging variants using the SKAT-O method. Functional implication of the associated rare variation was evaluated using cell-type epigenetic enrichment analyses. Results: A total of 41 consecutive CD patients were included; 3250 functional rare variants were identified (2682 damaging and 568 LoF variants). Two homozygous LoF mutations were found in HLA-B and HLA-DRB1 genes associated with lack of response and remission, respectively. Genome-wide LoF variants were enriched in epigenetic marks specific for the gastrointestinal tissue (colon, p = 4.11e-4; duodenum, p = 0.011). The burden of damaging variation in the TNF signaling pathway was associated with response to anti-TNF therapy (p = 0.016); damaging variants were enriched in epigenetic marks from CD8+ (p = 6.01e-4) and CD4+ (p = 0.032) T cells. Conclusions: Functional rare variants are involved in the response to anti-TNF therapy in CD. Cell-type enrichment analysis suggests that the gut mucosa and CD8+ T cells are the main mediators of this response., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by grants from the "Instituto de Salud Carlos III" (FIS.12/02557 and PI13/00041).